Optigo Biotherapeutics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1055 W Georgia St Ste 2100, Vancouver, B...Website
www.optigobio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Optigo Biotherapeutics
Optigo Biotherapeutics is a pre-clinical stage biotherapeutics company focused on developing innovative treatments for retinal neovascular diseases. Their proprietary platform technology aims to enhance the durability of intravitreal drugs, significantly reducing the frequency of injections required for patients. The company targets ophthalmology companies and seeks to partner with them to improve intravitreal therapies, ultimately aiming to prevent vision loss with fewer injections. Optigo's mission is to provide safer and more convenient treatment options for patients suffering from chronic ophthalmic diseases.Explore more
Optigo Biotherapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Optigo Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Optigo Biotherapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Optigo Biotherapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Optigo Biotherapeutics
Earning: See what the market has to say on Optigo Biotherapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Optigo Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Optigo Biotherapeutics launches new products
Check out if Optigo Biotherapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Optigo Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Optigo Biotherapeutics
Compare insights from companies similar to Optigo Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Optigo Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Optigo Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Optigo Biotherapeutics.
Optigo Biotherapeutics Tech Stack
A closer look at the technologies used by Optigo Biotherapeutics
Optigo Biotherapeutics News & Media
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
Optigo Bio Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at ARVO 2025
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Optigo Biotherapeutics
Sign Up For FreeTo access detailed company insights
Optigo Biotherapeutics is a pre-clinical stage biotherapeutics company focused on developing innovative treatments for retinal neovascular diseases. Their proprietary platform technology aims to enhance the durability of intravitreal drugs, significantly reducing the frequency of injections required for patients. The company targets ophthalmology c... Read More
